Serum-Free Medium Enhances the Therapeutic Effects of Umbilical Cord Mesenchymal Stromal Cells on a Murine Model for Acute Colitis

Wu, Xiaoyun; Wu, Daocheng; Ye, Mu; Zhao, Yijiao; Ma, Zhi-Jie

doi:10.3389/fbioe.2020.00586

Cited by 11 publications

(14 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, it was reported that UC-MSC cultured in a xeno-free medium showed an enhanced therapeutic effect in a mouse model for UC, compared with UC-MSC cultured in a conventional medium [ 294 ].…”

Section: New Technologies For Msc Cultures and Mass Production Of Sec...mentioning

confidence: 99%

Mesenchymal (Stem) Stromal Cells Based as New Therapeutic Alternative in Inflammatory Bowel Disease: Basic Mechanisms, Experimental and Clinical Evidence, and Challenges

Eiró

Fraile

González-Jubete

et al. 2022

IJMS

View full text Add to dashboard Cite

Inflammatory bowel diseases (IBD) are an example of chronic diseases affecting 40% of the population, which involved tissue damage and an inflammatory process not satisfactorily controlled with current therapies. Data suggest that mesenchymal stem cells (MSC) may be a therapeutic option for these processes, and especially for IBD, due to their multifactorial approaches such as anti-inflammatory, anti-oxidative stress, anti-apoptotic, anti-fibrotic, regenerative, angiogenic, anti-tumor, or anti-microbial. However, MSC therapy is associated with important limitations as safety issues, handling difficulties for therapeutic purposes, and high economic cost. MSC-derived secretome products (conditioned medium or extracellular vesicles) are therefore a therapeutic option in IBD as they exhibit similar effects to their parent cells and avoid the issues of cell therapy. In this review, we proposed further studies to choose the ideal tissue source of MSC to treat IBD, the implementation of new standardized production strategies, quality controls and the integration of other technologies, such as hydrogels, which may improve the therapeutic effects of derived-MSC secretome products in IBD.

show abstract

Section: New Technologies For Msc Cultures and Mass Production Of Sec...mentioning

confidence: 99%

Mesenchymal (Stem) Stromal Cells Based as New Therapeutic Alternative in Inflammatory Bowel Disease: Basic Mechanisms, Experimental and Clinical Evidence, and Challenges

Eiró

Fraile

González-Jubete

et al. 2022

IJMS

View full text Add to dashboard Cite

show abstract

“…Passage-5 P-ADSCs or H-ADSCs were seeded at 5×10 4 cells/well in 6-well plates for 12 h, and then treated with 10 ng/ml interferon-γ (IFN-γ) and 10 ng/ml tumor necrosis factor-α (TNF-α) separately or combined for 48 h. The contents of prostaglandin (PG)E 2 , interleukin (IL)-6, and TNF-α-induced protein 6 (TSG-6) in the culture media were analyzed using enzyme linked immunosorbent assay (ELISA) kits (R and D Systems, United States), according to supplied instructions, and indoleamine 2,3-dioxygenase (IDO) activity (kynurenine concentration) was measured as previously described (Wu et al, 2020b).…”

Section: Inflammatory Priming Assaymentioning

confidence: 99%

Adipose-Derived Stem Cells From Patients With Ulcerative Colitis Exhibit Impaired Immunosuppressive Function

Yao

et al. 2022

Front. Cell Dev. Biol.

Self Cite

View full text Add to dashboard Cite

Adipose-derived stem cells (ADSCs) are able to modulate the immune response and are used for treating ulcerative colitis (UC). However, it is possible that ADSCs from patients with inflammatory or autoimmune disorders may show defective immunosuppression. We investigated the use of ADSCs from UC patients for autologous cell treatment, specifically, ADSCs from healthy donors (H-ADSCs) and UC patients (P-ADSCs) in terms of various functions, including differentiation, proliferation, secretion, and immunosuppression. The efficacy of P-ADSCs for treating UC was examined in mouse models of acute or chronic colitis. Both H-ADSCs and P-ADSCs were similar in cell morphology, size, adipogenic differentiation capabilities, and cell surface markers. We found that P-ADSCs had lower proliferative capacity, cloning ability, and osteogenic and chondrogenic differentiation potential than H-ADSCs. P-ADSCs exhibited a diminished capacity to inhibit peripheral blood mononuclear cell proliferation, suppress CD25 and CD69 marker expression, decrease the production of inflammation-associated cytokines interferon-γ and tumor necrosis factor-α, and reduce their cytotoxic effect on A549 cells. When primed with inflammatory cytokines, P-ADSCs secreted lower levels of prostaglandin E2, indoleamine 2, 3-dioxygenase, and tumor necrosis factor-α–induced protein 6, which mediated their reduced immunopotency. Moreover, P-ADSCs exhibited weaker therapeutic effects than H-ADSCs, determined by disease activity, histology, myeloperoxidase activity, and body weight. These findings indicate that the immunosuppressive properties of ASCs are affected by donor metabolic characteristics. This study shows, for the first time, the presence of defective ADSC immunosuppression in UC, indicating that autologous transplantation of ADSCs may be inappropriate for patients with UC.

show abstract

“…CM helps to maintain the increased paracrine factor gradient between the diseased organ and the stem cell niche to accelerate the recovery process[ 94 ]. Kang et al [ 95 ] and Wu et al [ 96 ] showed that using different culture media without foetal bovine serum during the in vitro expansion of BMMSCs enhances the immunomodulatory effect of MSCs in an in vivo model of IBD. Other researchers then supplemented culture media with different compounds, such as a combination of aspirin, b-fibroblast growth factor (b-FGF), all-trans retinoic acid and modified neuronal medium (MNM) or the combination of activin A, b-FGF and platelet lysates.…”

Section: Enhancement Of the Therapeutic Effects Of Mscs On Ibdmentioning

confidence: 99%

Strategies to improve the effect of mesenchymal stem cell therapy on inflammatory bowel disease

Shi¹,

Yang²

2022

World J Stem Cells

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD) includes Crohn’s disease and ulcerative colitis and is an idiopathic, chronic inflammatory disease of the colonic mucosa. The occurrence of IBD, causes irreversible damage to the colon and increases the risk of carcinoma. The routine clinical treatment of IBD includes drug treatment, endoscopic treatment and surgery. The vast majority of patients are treated with drugs and biological agents, but the complete cure of IBD is difficult. Mesenchymal stem cells (MSCs) have become a new type of cell therapy for the treatment of IBD due to their immunomodulatory and nutritional functions, which have been confirmed in many clinical trials. This review discusses some potential mechanisms of MSCs in the treatment of IBD, summarizes the experimental results, and provides new insights to enhance the therapeutic effects of MSCs in future applications.

show abstract

Serum-Free Medium Enhances the Therapeutic Effects of Umbilical Cord Mesenchymal Stromal Cells on a Murine Model for Acute Colitis

Cited by 11 publications

References 57 publications

Mesenchymal (Stem) Stromal Cells Based as New Therapeutic Alternative in Inflammatory Bowel Disease: Basic Mechanisms, Experimental and Clinical Evidence, and Challenges

Mesenchymal (Stem) Stromal Cells Based as New Therapeutic Alternative in Inflammatory Bowel Disease: Basic Mechanisms, Experimental and Clinical Evidence, and Challenges

Adipose-Derived Stem Cells From Patients With Ulcerative Colitis Exhibit Impaired Immunosuppressive Function

Strategies to improve the effect of mesenchymal stem cell therapy on inflammatory bowel disease

Contact Info

Product

Resources

About